Genor Biopharma Holdings Limited (6998.HK)
HKD 1.66
(-5.68%)
HKD 1.66
(-5.68%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.15 Million CNY | -74.97% |
| 2022 | 28.58 Million CNY | -50.21% |
| 2021 | 57.4 Million CNY | 84.84% |
| 2020 | 31.05 Million CNY | -25.63% |
| 2019 | 41.76 Million CNY | -6.67% |
| 2018 | 44.75 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - CNY | -100.0% |
| 2024 Q2 | - CNY | 0.0% |
| 2023 Q1 | 23.69 Million CNY | -17.12% |
| 2023 FY | 7.15 Million CNY | -74.97% |
| 2023 Q4 | 7.15 Million CNY | 82.34% |
| 2023 Q3 | 3.92 Million CNY | -88.31% |
| 2023 Q2 | 33.56 Million CNY | 41.67% |
| 2022 Q2 | 54.8 Million CNY | 36.92% |
| 2022 Q1 | 40.02 Million CNY | -30.27% |
| 2022 Q4 | 28.58 Million CNY | 30.99% |
| 2022 FY | 28.58 Million CNY | -50.21% |
| 2022 Q3 | 21.82 Million CNY | -60.18% |
| 2021 FY | 57.4 Million CNY | 84.84% |
| 2021 Q1 | 17.37 Million CNY | 8.52% |
| 2021 Q4 | 57.4 Million CNY | 15.26% |
| 2021 Q3 | 49.8 Million CNY | 54.48% |
| 2021 Q2 | 32.24 Million CNY | 85.53% |
| 2020 FY | 31.05 Million CNY | -25.63% |
| 2020 Q1 | 40.23 Million CNY | 0.0% |
| 2020 Q2 | - CNY | -100.0% |
| 2020 Q4 | 16.01 Million CNY | 0.0% |
| 2020 Q3 | 16.01 Million CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 41.76 Million CNY | -6.67% |
| 2018 FY | 44.75 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | 86.466% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 99.879% |